消退期视网膜母细胞瘤患眼的经角膜玻璃体切除术
该回顾性病例系列描述了5例消退期视网膜母细胞瘤(D组/ct2b)患眼接受经角膜玻璃体切除术的技术,采用径向角膜切口、Versa HD LenZ联合RESIGHT自上而下观察,未使用化疗或冷冻治疗,手术目标达成、视力稳定且平均随访7.6个月未见肿瘤播散。
要点
- 5例消退期视网膜母细胞瘤患眼共行8次玻璃体切除术,适应证包括人工晶体纤维化、玻璃体积血、白内障、视网膜脱离及硅油取出。
- 采用23-G或25-G穿刺系统做径向角膜切口,Versa HD LenZ联合RESIGHT实现自上而下观察,未使用化疗或冷冻治疗。
- 手术目标达成、视力稳定,平均随访7.6个月未见视网膜母细胞瘤播散。
核心结论
- 该经角膜玻璃体切除术技术可用于消退期视网膜母细胞瘤患眼,允许使用Versa HD LenZ进行自上而下观察。
研究设计与样本
- 回顾性图表审查,纳入洛杉矶儿童医院5例连续消退期视网膜母细胞瘤超过12个月(D组/ct2b)患者,于2022年11月至2023年12月期间接受玻璃体切除术。
主要发现
- 5例患者共行8次玻璃体切除术,适应证包括人工晶体纤维化、玻璃体积血、白内障、视网膜脱离和硅油取出。
- 首次玻璃体切除术平均年龄6.2岁(范围2-9岁),距末次视网膜母细胞瘤治疗平均时间50.4个月(范围20-82个月)。
- 手术目标达成、视力保持稳定,平均随访7.6个月(范围3-12个月)未见视网膜母细胞瘤播散。
关键数值与推荐
- 径向角膜切口使用23-G或25-G穿刺系统,采用Versa HD LenZ(Oculus)联合RESIGHT(Zeiss)进行自上而下可视化。
- 未使用化疗或冷冻治疗,伤口以10-0聚乳酸羟基乙酸910缝线(Vicryl,Ethicon)平行于角膜缘缝合,并最终用水冲洗以裂解潜在的视网膜母细胞瘤细胞。
临床怎么用
- 作者认为该技术可能免去化疗或冷冻治疗的需要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Current treatments for retinoblastoma facilitate globe salvage but can result in vitreoretinal disorders that may require surgery. There is controversy on surgical approaches in eyes with retinoblastoma. Here, we describe a transcorneal vitrectomy approach that avoids the use of chemotherapy or cryotherapy. METHODS: Retrospective chart review was performed on five consecutive patients with regressed retinoblastoma for >12 months (Group D/ct2b) at Children's Hospital Los Angeles who had vitrectomy between November 2022 and December 2023. RESULTS: Five patients underwent eight vitrectomies for various indications including intraocular lens fibrosis, vitreous hemorrhage, cataract, retinal detachment, and silicone oil removal. Mean age at first vitrectomy was 6.2 years (range: 2-9 years); mean time from last retinoblastoma treatment was 50.4 months (range: 20-82 months). Radially oriented corneal incisions were made with the 23-G or 25-G trocar system, and the Versa HD LenZ (Oculus) was used with the RESIGHT (Zeiss) for top-down visualization. Neither chemotherapy nor cryotherapy was used. Wounds were sutured parallel to the limbus with 10-0 polyglactin 910 suture (Vicryl, Ethicon), and a final water rinse was performed to lyse any potential retinoblastoma cells. Surgical objectives were achieved, vision remained stable, and no retinoblastoma spread was noted with a mean follow-up of 7.6 months (range: 3-12 months). CONCLUSION: This vitrectomy technique for eyes with regressed retinoblastoma permits top-down viewing with the Versa HD LenZ. Radial placement of corneal wounds avoids suturing through the uveal tract, and a postsurgical water rinse lyses any retinoblastoma cells. This approach may obviate the need for chemotherapeutics or cryotherapy.
引用
- Bao YK, Sanchez GM, Lee TC, et al. Transcorneal Vitrectomy In Eyes With Regressed Retinoblastoma. Retina. 2024. PMID: 39784483. doi:10.1097/IAE.0000000000004178
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。